Treatment Interruption Fails Test in Gastrointestinal Stromal Tumors (GIST) , Institut Gustave Roussy Study
MedPageToday -- More than 80% of patients with gastrointestinal stromal tumors (GIST) had progressive disease after discontinuing long-term treatment with imatinib (Gleevec), investigators in a multicenter French trial reported.